Abiopharma

🔍 HO SUI MAN (Executive)

Company: UNIVERSAL ELECTRONICS INC (UEIC)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 30,000 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 50,846.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 100,000 shares of Performance Stock Units (Derivative)
  Date: 2026-08-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 100,000.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Acquired 100,000 shares of Performance Stock Units (Derivative)
  Date: 2026-08-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 100,000.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Acquired 30,000 shares of Employee Stock Option (Rt to Buy) at $4.56 per share (Derivative)
  Date: 2026-08-31 | Code: A | Expires: 2036-08-31 | equity_swap_involved: 0 | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F5, F5

Footnotes:

• F1: Grant of restricted stock units ("RSUs") granted on August 31, 2026, each of which represents a contingent right to receive one share of UEI common stock, with 1/3 of the RSUs vesting on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.
• F2: Includes prior awards of RSUs previously reported in Table II of Form 3. The total reported in column 5 includes the 30,000 newly awarded RSUs, 6,133 RSUs previously reported in Table II, and 14,713 shares of common stock.
• F3: Each performance stock unit represents a contingent right to receive one share of UEI common stock.
• F4: The performance stock unit award was approved by the Compensation Committee of the Board of Directors on August 31, 2026 with a grant date of August 31, 2026. The performance stock unit award will vest in three tranches with one stock market condition and three service conditions. Each tranche will vest only when both the stock price market and service conditions have been achieved. The stock price market condition must be met on or by the fifth anniversary of the grant date (August 31, 2031). Any unvested tranche will expire at close of business on August 31, 2031.
• F5: The nonstatutory stock option award was approved by the Compensation Committee of the Board of Directors on August 31, 2026 with a grant date of August 31, 2026. The stock option award will vest over a 3-year vesting schedule with 33.33% on August 31, 2027, 33.33% on August 31, 2028 and the remainder vesting on August 31, 2029.